Wegovy (semaglutide) is a prescription medication for chronic weight management, and its most common side effects are gastrointestinal in nature, including nausea, diarrhea, vomiting, constipation, and abdominal pain. These effects are often dose-dependent and may subside as the body adjusts to the medication. While these are the most frequently reported issues, it’s crucial to have a comprehensive understanding of the full spectrum of potential side effects, their prevalence, and management strategies to use the treatment safely and effectively.
Wegovy belongs to a class of drugs called GLP-1 receptor agonists. It works by mimicking a hormone that targets areas of the brain involved in appetite regulation, leading to reduced hunger and calorie intake, while also slowing down the emptying of the stomach. This very mechanism of action is the primary reason for its high efficacy and also for its most common adverse events. The gastrointestinal system is directly affected, which explains why up to 74% of users in clinical trials experienced at least one GI side effect.
Prevalence and Severity of Gastrointestinal Side Effects
The following table outlines the incidence of common GI side effects as observed in the STEP clinical trial program, which involved thousands of participants over 68 weeks. The data compares the percentage of people experiencing these effects with Wegovy versus a placebo (a dummy treatment).
| Side Effect | Wegovy (2.4 mg) | Placebo | Notes on Management |
|---|---|---|---|
| Nausea | 44.2% | 16.1% | Typically occurs during dose escalation. Eating smaller, bland, low-fat meals can help. |
| Diarrhea | 29.5% | 15.9% | Staying hydrated is critical. May be intermittent. |
| Vomiting | 24.5% | 6.3% | More common when increasing the dose. If persistent, medical advice is needed. |
| Constipation | 23.4% | 11.4% | Increasing dietary fiber and fluid intake is the first line of management. |
| Abdominal Pain | 20.9% | 9.9% | Can range from mild discomfort to more significant pain. |
A key takeaway from this data is that while these side effects are common, they are often transient and mild to moderate in severity. The clinical trials demonstrated that a majority of these events occurred during the dose-escalation phase (the first 16-20 weeks when the dose is gradually increased) and decreased in frequency over time as patients continued on the maintenance dose. Only a small percentage of participants discontinued the trial due to gastrointestinal side effects (around 4-5% for Wegovy compared to less than 1% for placebo), suggesting that most people are able to tolerate and manage them.
Less Common but Serious Side Effects Requiring Vigilance
Beyond the common GI issues, Wegovy carries a wegovy which details important warnings. It is essential for patients and healthcare providers to be aware of these potential risks.
Risk of Thyroid C-Cell Tumors: Wegovy has a black box warning, the FDA’s most stringent alert, regarding the potential risk of thyroid C-cell tumors, including cancer. In rodent studies, semaglutide caused these tumors. It is unknown if Wegovy causes these tumors in humans, but its use is contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should be advised to report symptoms like a lump in the neck, hoarseness, difficulty swallowing, or shortness of breath.
Pancreatitis (Inflammation of the Pancreas): There have been post-marketing reports of acute pancreatitis. Patients should be warned to seek immediate medical attention if they experience severe, persistent abdominal pain that may radiate to the back, with or without vomiting.
Gallbladder Problems: Substantial weight loss can increase the risk of gallstones and other gallbladder diseases. In trials, 1.6% of Wegovy users experienced cholelithiasis (gallstones) compared to 0.7% on placebo. Symptoms can include upper abdominal pain, fever, and jaundice (yellowing of the skin or eyes).
Hypoglycemia (Low Blood Sugar): When Wegovy is used in conjunction with other medications for type 2 diabetes, such as insulin or sulfonylureas, the risk of hypoglycemia increases significantly. It is crucial to monitor blood sugar levels closely and for healthcare providers to consider reducing the dose of these concomitant diabetes medications.
Acute Kidney Injury: primarily due to severe nausea, vomiting, diarrhea, or dehydration. Patients with pre-existing kidney disease or those taking diuretics need to be especially cautious and maintain adequate hydration.
Increased Heart Rate: Wegovy can cause a sustained increase in resting heart rate. In clinical trials, the mean increase was about 1-4 beats per minute. Patients with underlying cardiovascular conditions should be monitored for this effect.
Patient-Specific Considerations and Contraindications
Not everyone is a candidate for Wegovy. A thorough medical evaluation is necessary before starting treatment. Key considerations include:
Pregnancy and Breastfeeding: Wegovy is contraindicated during pregnancy due to the potential for fetal harm based on animal studies. It is recommended to discontinue Wegovy at least 2 months before a planned pregnancy. There are no data on the presence of semaglutide in human breast milk, so a risk-benefit decision must be made by the prescribing physician.
Personal or Family History: As mentioned, a history of MTC or MEN 2 is an absolute contraindication. A history of pancreatitis is also a significant consideration, and the drug should be used with extreme caution, if at all, in such patients.
Mental Health: Weight loss can sometimes unmask or affect underlying mental health conditions. While not a direct side effect of the drug, the journey of significant body change should be supported with appropriate counseling or resources if needed.
Practical Strategies for Managing Side Effects
Success with Wegovy often hinges on proactive management of side effects. Here are evidence-based and practical tips:
For GI Issues: The “start low, go slow” dosing schedule is designed to allow your body to adapt. Adhering strictly to this schedule is the first defense. Dietary modifications are powerful: opt for smaller, more frequent meals instead of three large ones. Focus on bland, easy-to-digest foods (bananas, rice, applesauce, toast – the BRAT diet) when nausea is present. Avoid high-fat, greasy, or spicy foods that can exacerbate symptoms. Staying well-hydrated with water or electrolyte solutions is non-negotiable, especially if experiencing vomiting or diarrhea.
For Constipation: Increase your intake of water and soluble fiber (found in oats, peas, beans, apples, carrots). Regular, mild physical activity like walking can also stimulate bowel motility. If these measures are insufficient, a healthcare provider may recommend a gentle over-the-counter stool softener.
Overall Hydration: This cannot be overstated. Dehydration is a common trigger for several side effects, including kidney issues and severe constipation. Aim for clear or pale yellow urine as a simple indicator of good hydration.
Open Communication with Your Healthcare Provider: This is the most critical strategy. Report any side effects, especially if they are severe or persistent. Do not hesitate to call your doctor about severe abdominal pain, symptoms of pancreatitis, or signs of a thyroid tumor. They can provide personalized advice, manage dose adjustments, or rule out more serious conditions. They are your partner in navigating this treatment successfully.